Mycobacterium tuberculosis IgG ELISA Kit, Sensitive (DEIA384)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
serum, plasma
Species Reactivity
Human
Intended Use
The Mycobacterium tuberculosis IgG antibody ELISA kit has been designed for the detection andthe quantitative determination of specific IgG antibodies against Mycobacterium tuberculosis in serum and plasma.
Contents of Kit
1. Microtiter Strips
2. Calibrator A(Negative Control)
3. Calibrator B(Cut-Off Standard)
4. Calibrator C(Weak positive Control)
5. Enzyme Conjugate
6. Substrate
7. Stop Solution
8. Sample Diluent
9. Washing Buffer
10. Plastic Foils
Storage
For more detailed information, please download the following document on our website.
Precision
Intra-assay-Precision: 7.6%
Inter-assay-Precision: 9.4%
Inter-Lot-Precision: 3.1-9.9%
Sensitivity
1.09 U/mL

Citations


Have you cited DEIA384 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Tuberculosis vaccine: A journey from BCG to present

LIFE SCIENCES

Authors: Fatima, Samreen; Kumari, Anjna; Das, Gobardhan; Dwivedi, Ved Prakash

Tuberculosis (TB) is the leading cause of death worldwide due to an infectious disease, causing around 1.6 million deaths each year. This situation has become more complicated by the emergence of drug-resistant Mycobacterium tuberculosis (M.tb) and HIV-TB co-infection, which has significantly worsened TB prognosis and treatment. Despite years of intensive research, Bacille Calmette-Guerin (BCG) remains the only licensed vaccine and has variable efficacy. It provides protection against childhood TB but is not effective in adult pulmonary TB. As a result of intense research in understanding TB vaccinology, there are many new vaccine candidates in clinical development and many more in pre-clinical trials which aim either to replace or boost BCG vaccine. This review discusses the history of BCG vaccine development and summarizes limitations of the current vaccine strategy and recent advances in improving BCG immunization along with other new vaccines in clinical trials which are promising candidates for the future tuberculosis vaccinology program.

Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children

PEDIATRIC INFECTIOUS DISEASE JOURNAL

Authors: Srivastava, Shashikant; van Zyl, Johanna; Cirrincione, Kayle; Martin, Katherine; Thomas, Tania; Deshpande, Devyani; Alffenaar, Jan-William; Seddon, James A.; Gumbo, Tawanda

Background: Ceftazidime-avibactam is an effective agent for the treatment of tuberculosis (TB) but requires frequent administration because of a short half-life. Due to a longer half-life, ceftriaxone could allow intermittent dosing. Methods: First, we identified the MIC of ceftriaxone with 15 mg/L avibactam in 30 clinical Mycobacterium tuberculosis isolates. Next, 2 ceftriaxone exposure-effect studies in the intracellular hollow fiber model of TB (HFS-TB) that mimics disseminated disease in young children, were performed. Ceftriaxone was administered once or twice daily for 28 days to explore percentage of time that the concentration persisted above MIC (%T-MIC) ranging from 0 to 100%. In a third HFS-TB experiment, the "double cephalosporin" regimen of ceftazidime-ceftriaxone-avibactam was examined and analyzed using Bliss Independence. Conclusion: The MIC99 of the clinical strains was 32 mg/L, in the presence of 15 mg/L avibactam. Ceftriaxone %T-MIC <42 had no microbial effect in the HFS-TB, %T-MIC >54% demonstrated a 4.1 log(10) colony-forming units per milliliter M. tuberculosis kill, while %T-MIC mediating E-max was 68%. The "double cephalosporin" combination was highly synergistic. Monte Carlo experiments of 10,000 subjects identified the optimal ceftriaxone dose as 100 mg/kg twice a day. Conclusion: The combination of ceftriaxone-avibactam at 100 mg/kg could achieve E-max in >90% of children. The ceftriaxone potent activity M. tuberculosis could potentially shorten therapy in children with disseminated TB.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket